The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies.
In this third instalment of the five-part, festive series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Mark Andrews, investment director of life sciences funds at Brit
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.